€118.00
Product information
| Active substances | POLYNUCLEOTIDES |
|---|---|
| Manufacturer | Croma |
| Pack size | 1 x 2ml Pre-Filled Syringes |
| Strength | 15mg/2ml |
We guarantee your order will arrive quickly. Most parcels are delivered within 1–3 business days, ensuring you get the products you need when you need them.
Enjoy personalized support with a dedicated account manager. From product selection to tracking, you’ll always have a trusted partner by your side.
Shop confidently from our wide range of 300+ verified products. Every item is ready to ship, giving you reliable access to trusted medical solutions.
We supply only authentic products, backed by full traceability. Every order comes with confidence, transparency, and assurance of verified sourcing.
CROMA PhilArt EYE is a polynucleotide-based injectable treatment designed for rejuvenating the delicate skin around the eye contour. This advanced skin booster utilizes PN-HPT® (Polynucleotides Highly Purified Technology) to stimulate dermal regeneration and enhance skin quality in sensitive periocular areas.
The product contains 15 mg of polynucleotides per 2 ml formulation, engineered for use in eye rejuvenation procedures. Each package includes one pre-filled syringe with two 30G ½ needles for precise administration.
Professional administration of PhilArt requires precise technique and proper dosing protocols. The recommended dosage is 1–2 ml per session, administered intradermally using the provided 30G needles. Treatment sessions should be spaced 14–21 days apart, with an initial protocol of 3–4 sessions for optimal results.
The eye injection technique involves serial puncture or linear retrograde methods, with injection points spaced 0.5–1cm apart. Areas treated include the periorbital region and eyebrow arches, ensuring even distribution for consistent outcomes.
The active ingredient in CROMA PhilArt EYE is polynucleotide PN-HPT® at a concentration of 15mg per 2ml. This highly purified technology enhances cellular regeneration and promotes skin repair mechanisms. The biocompatible formulation minimizes adverse reactions while maximizing therapeutic benefits.
CROMA has developed this specialized polynucleotide blend to optimize the balance between efficacy and safety for delicate skin applications. The formulation excludes lidocaine, making it suitable for patients with local anesthetic sensitivities.
CROMA PhilArt EYE—1x2ml requires specific storage conditions to maintain product integrity and efficacy. Store between 2°C and 25°C, protecting from light exposure and freezing temperatures. The product should be kept in its original packaging until use, ensuring sterility and maintaining its potency. Proper storage protocols are essential for maintaining the stability of polynucleotides and ensuring optimal therapeutic outcomes during treatment procedures.
PhilArt EYE dermal filler product is contraindicated in patients with known allergies to polynucleotides or formulation components. Active skin infections or inflammation in treatment areas preclude use. Pregnancy, breastfeeding, and autoimmune disorders represent absolute contraindications. Products should not be administered to individuals with bleeding disorders or those taking anticoagulant medications without proper medical evaluation.
Healthcare professionals must exercise caution during PhilArt administration to prevent vascular complications. Proper injection depth and technique of all CROMA products are crucial for patient safety. Combining this with other dermal fillers or aesthetic treatments requires careful consideration and appropriate timing intervals. Patients should be monitored for immediate adverse reactions during and after treatment procedures.
CROMA Pharma GmbH manufactures PhilArt EYE under strict quality control standards, ensuring compliance with CE marking requirements for medical devices. When you buy CROMA PhilArt EYE or order CROMA PhilArt EYE, you receive a product with complete batch documentation and regulatory compliance certification, ensuring professional-grade quality for medical practice applications.
